Targets – who needs them? Success with statin therapies

Keywords

Computer science

References

• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).Славко Андрей Александрович — 2003
• Statins as the new aspirinU. Ravnskov — 2002
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.S. Féasson — 2002
• Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid‐lowering drugsPeter Lindgren, Fredrik Borgström, Jan Stålhammar — 2007
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.Rory Collins, Jane Armitage, Sarah Parish — 2003
• Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.John R. Crouse, Joel S. Raichlen, Ward A. Riley — 2007
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington — 2004
• Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).Gregg C. Fonarow, Anna Gawlinski, Samira Moughrabi — 2001
• Attaining United States and European Guideline LDL-cholesterol Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study)Fausto Garmendia, Alan S. Brown, István Reiber — 2000
• Impact of adherence to statins on coronary artery disease in primary prevention.Marie‐Hélène Bouchard, Alice Dragomir, Lucie Blais — 2007
• Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.AD Sniderman, C.D. Furberg, Anthony Keech — 2003
• High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.G. Walldius, Ingmar Jungner, Ingar Holme — 2001
• How to lose a billion poundsJames Moon, Richard Bogle — 2007
• The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003Björn Eliasson, Jan Cederholm, Peter M. Nilsson — 2005
• Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).Peter Sever, Neil R Poulter, Björn Dahlöf — 2005
• Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003.Richard M. Cubbon, Stephen G. Wheatcroft, Peter J. Grant — 2006
• Attaining United States and European Guideline LDL-C Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study)Dimitri P. Mikhailidis, Anthony S. Wierzbicki — 2000
• Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 DiabetesRobert H. Knopp, Michael C dʼEmden, J. G. Smilde — 2006
• Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.Haruo Nakamura, Kikuo Arakawa, Hiroshige Itakura — 2006
• Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) studyÉric Van Ganse, Laurent Laforest, E. Alemao — 2005

Cited by

• Statin wars: efficacy vs. costAnthony S. Wierzbicki — 2011

Related papers

No related papers recorded.